awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33399867-29AA84EE-ED65-4772-BF36-FEFE7CFBB88A
Q33399867-29AA84EE-ED65-4772-BF36-FEFE7CFBB88A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33399867-29AA84EE-ED65-4772-BF36-FEFE7CFBB88A
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
P2860
Q33399867-29AA84EE-ED65-4772-BF36-FEFE7CFBB88A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33399867-29AA84EE-ED65-4772-BF36-FEFE7CFBB88A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
88f3cd06f84f1d95ed0fecfd6c03b5a1934438f9
P2860
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.